Tick-Borne Encephalitis Virus
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 12305
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tick-borne encephalitis (TBE) is an emerging vector-borne disease in Europe caused by tick-borne encephalitis virus (TBEV), which belongs to the Flaviviridae family. The number of TBE cases in Europe varies depending on the country and ranges from a few up to 1000 cases per year. There are three distinct clinical forms of TBE: meningitis, meningoencephalitis, meningoencephalomyelitis. In patients with meningoencephalitis and meningoencephalomyelitis, the course of the disease is more severe. The mortality rate is 1%–4%, and a fatal outcome is usually observed in the elderly or immunodeficient patients, but occasionally in young persons.
Although most patients quickly recover from the disease, some require further neurological and psychiatric treatment due to persisting symptoms. So‐called post‐encephalitic TBE syndrome was described in 35%–58% of patients. This may cause long‐term morbidity that often affects the patient’s quality of life and forces a change in lifestyle. The most commonly reported symptoms were cognitive or neuropsychiatric complaints, balance disorders, headache, dysphasia, hearing defects, and limb paresis.
The pathogenesis of different clinical presentations and sequelae development in TBE has not been fully recognized so far. TBE virus neurotropism preferentially targets large neurons of anterior horns, medulla oblongata, pons, dentate nucleus, Purkinje cells, and striatum. It was confirmed that the disease may lead to nerve cell destruction.
Although there is a vaccine available, treatment remains symptomatic.
This Special Issue will focus on, but not exclusively, the following areas of research:
- Epidemiological aspects of TBE
- Pathogenesis and diagnostics of TBE in humans
- Development of sequelae after TBE
- Approach to prevention and treatment
- Development of novel therapeutic strategies against TBE complications
Prof. Dr. Anna Moniuszko-Malinowska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TBE
- TBEV
- tick
- encephalitis
- meningitis